Class summary at a glance.

Every drug in the alpha-Adrenergic Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $479.2Mcombined across class
Total Rx claims: 33.3M9.7M unique beneficiaries
Generic mfrs (active): 49across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Carvedilol

Brand: Coreg · 23.9M Part D claims (CY24) · 7.0M beneficiaries · First FDA approval: 2007-09-05

12 generic mfrs 0 plans require PA

Low NADAC$0.017

→

Avg plan cost$0.945

Part D spend $265.2M 55× spread, current vs floor

Class share

55%

of class CY24 spend

View profile →

Doxazosin

Brand: Cardura · 3.3M Part D claims (CY24) · 996K beneficiaries · First FDA approval: 2000-10-18

9 generic mfrs 0 plans require PA

Low NADAC$0.069

→

Avg plan cost$0.164

Part D spend $54.9M 2× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Terazosin

Brand: TEZRULY · 2.0M Part D claims (CY24) · 607K beneficiaries · First FDA approval: 1998-03-30

5 generic mfrs 0 plans require PA

Low NADAC$0.109

→

Avg plan cost$0.121

Part D spend $42.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Alfuzosin

Brand: Uroxatral · 1.7M Part D claims (CY24) · 588K beneficiaries · First FDA approval: 2011-11-22

4 generic mfrs 0 plans require PA

Low NADAC$0.111

→

Avg plan cost$0.111

Part D spend $39.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Silodosin

Brand: RAPAFLO · 459K Part D claims (CY24) · 154K beneficiaries · First FDA approval: 2009-03-23

10 generic mfrs 0 plans require PA

Low NADAC$0.272

→

Avg plan cost$1.01

Part D spend $39.6M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Prazosin

2.0M Part D claims (CY24) · 410K beneficiaries · First FDA approval: 1989-02-28

9 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.085

→

Avg plan cost$0.107

Part D spend $37.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.